bonyf N.V. (MLBON.PA EURONEXT) up 21.21% to €4.80 on 29 Jan 2026: liquidity and outlook
bonyf N.V. (MLBON.PA) jumped 21.21% to €4.80 on 29 Jan 2026, making it one of today’s largest percentage movers on EURONEXT. MLBON.PA stock rose from a previous close of €3.96 with only 2 shares reported traded, underlining a sharp price swing on very low liquidity. The move follows no public earnings release, so traders are weighing short-term technicals against thin market depth and stretched valuation metrics.
MLBON.PA stock: Price action and volume
The key price fact is a 21.21% one-day gain to €4.80 from €3.96. Volume was 2 versus an average volume of 8, so the percentage move reflects low trade count rather than broad market interest. One result: spreads and execution risk are elevated, and a single block trade can swing the price materially.
For active traders the takeaway is clear: the stock shows volatile intraday behaviour with relVolume 0.25 and thin order book depth on EURONEXT, which increases slippage risk for larger orders.
Business snapshot and sector context
bonyf N.V. produces oral and dental care products such as PerioTabs and AphtoFix and is listed on EURONEXT in Europe. The company’s industry is Medical – Instruments & Supplies, inside the broader Healthcare sector.
Compared with the healthcare sector average PE of 34.44, bonyf’s negative EPS and losses stand out. Investors should weigh product-level demand against sector performance and peer benchmarks.
Financials and valuation highlights
Key metrics show mixed signals: market cap €2,825,280.00, shares outstanding 588,600, EPS -1.77, and reported PE -2.71. Book value per share is €4.49 and price-to-book is 1.07, which implies the market values bonyf near its book per share. Price-to-sales is 10.04, reflecting thin revenue relative to market value.
Liquidity metrics are weak: current ratio 0.51 and days sales outstanding 409.75 indicate working capital strain. Conversely, free cash flow yield is reported at 20.16%, though that figure is influenced by small absolute cash flows and per-share scaling. Investors should treat ratio extremes cautiously given the tiny market cap and low float.
Technical and trading signals
Short-term technicals are mixed. The ADX reads 100.00, signaling a strong trend driven by today’s gap, while MACD histogram is -0.16, indicating a lack of bullish momentum confirmation on moving averages. Keltner middle band is €5.82, which places the price slightly below some mid-channel measures.
Given the average 50-day price €8.84 and 200-day price €12.60, the current price is below moving averages, suggesting mean-reversion potential but also persistent downtrend over longer windows.
Meyka AI rates MLBON.PA with a score out of 100
Meyka AI rates MLBON.PA with a score of 61.25 out of 100 — Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. DISCLAIMER: This grade is informational only and not financial advice.
Meyka AI’s forecast model projects a monthly target of €5.50 and a yearly level of €4.87, compared with the current price of €4.80. The monthly projection implies an implied upside of 14.58%, while the yearly forecast implies 1.53% upside. Forecasts are model-based projections and not guarantees.
Risks, catalysts and short-term outlook
Primary risks are continued low liquidity, negative EPS, stretched receivables (DSO 409.75), and a weak current ratio 0.51. Large shareholders or block trades can move the price quickly.
Catalysts to watch: any commercial contracts for PerioTabs or denture lines, regulatory updates, or a clear improvement in working capital metrics. Absent new volume-driving news, price moves may remain sporadic and gap-driven.
Final Thoughts
Today’s 21.21% intraday rise to €4.80 put MLBON.PA stock in focus, but the advance occurred on only 2 shares traded, exposing the move to reversal risk. Valuation is mixed: price-to-book 1.07 and book value per share €4.49 suggest limited downside to tangible equity, while negative EPS -1.77 and price-to-sales 10.04 flag operational pressure. Meyka AI’s model projects a near-term price of €5.50 (monthly) and a yearly level around €4.87, implying short-term upside of 14.58% and modest 12-month upside of 1.53% from today’s price. For traders, the stock may present short-term momentum opportunities, but investors should demand improved liquidity and clearer revenue traction before increasing exposure. We note a realistic 12-month price target range of €4.00–€8.00 depending on commercial progress and liquidity, with downside risk near the recent low €3.96. Always consider position sizing and execution risk given the tiny market cap €2,825,280.00 and thin float. Meyka AI provides this as AI-powered market analysis, not investment advice.
FAQs
What drove MLBON.PA stock higher on 29 Jan 2026?
The 21.21% rise to €4.80 occurred on extremely low volume (2 shares). There was no earnings release; the move appears driven by isolated trades rather than broad news or consensus upgrades.
How does bonyf’s valuation compare with its healthcare peers?
bonyf shows a negative EPS and PE, while the healthcare sector average PE is about 34.44. bonyf’s PB is 1.07, below many peers, but thin revenues and high price-to-sales 10.04 make comparisons imperfect.
What is the Meyka AI forecast for MLBON.PA stock?
Meyka AI’s model projects a monthly level of €5.50 and a yearly level of €4.87 versus the current €4.80. These are model projections and not guarantees; liquidity and fundamental news will drive real outcomes.
Should I trade MLBON.PA on this move?
Trading is possible for short-term momentum but carries high execution risk due to low volume and wide spreads. Limit orders and strict risk controls are essential; consider small position sizes until liquidity improves.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
